Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum

Conferencesonpiretigene isteparvovecMCO-010Positive

AI Analysis

Summary

Nanoscope Therapeutics will present Phase 2 randomized controlled trial data on sonpiretigene isteparvovec for macular degeneration and 4-year extension study data on MCO-010 for retinitis pigmentosa at the 26th Euretina Congress.

Clinical Trial Data

Phase

Phase 2

Importance:5/10

Sentiment:

0.50

optogenetic therapymacular degenerationretinitis pigmentosaconference presentationPhase 2 dataextension study

Related Companies

$TRAX

Read the original article

Published by PR Newswire Clinical Trials on September 23, 2026 11:04 AM

Read Original